Literature DB >> 14761202

Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.

Shengquan Liu1, Chad W Brown, K Darrell Berlin, Aridam Dhar, Suresh Guruswamy, David Brown, Ginger J Gardner, Michael J Birrer, Doris M Benbrook.   

Abstract

Regulation of growth, differentiation, and apoptosis by synthetic retinoids can occur through mechanisms that are dependent and independent of their ability to bind and activate nuclear retinoic acid receptors. The objective of this study was to determine if increasing flexibility of the heteroarotinoid structure would affect the specificity of the synthetic retinoids for the receptors and for their regulation of cancerous and nonmalignant cells. Methods were developed to produce the first examples of heteroarotinoids 15a-15h, which contain urea and/or thiourea linking groups between two aryl rings. Substituents at the para position of the single phenyl ring were either an ester, a nitro group, or a sulfonamide group. Ovarian cancer cell lines Caov-3, OVCAR-3, SK-OV-3, UCI-101, and 222 were utilized, and the inhibitory prowess of the heteroarotinoids was referenced to that of 4-HPR (25). Similar to 4-HPR (25), the heteroarotinoids inhibited growth of all cell lines at micromolar concentrations. Although the heteroarotinoids did not activate retinoic acid receptors, the agents induced potent growth inhibition against the cancer cells with weak activity against normal and benign cells. The growth inhibition was associated with cell loss and induction of reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14761202     DOI: 10.1021/jm030346v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

1.  Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Authors:  Satish K Ramraj; Sugantha P Elayapillai; Richard C Pelikan; Yan D Zhao; Zitha R Isingizwe; Amy L Kennedy; Stanley A Lightfoot; Doris M Benbrook
Journal:  Int J Cancer       Date:  2020-01-08       Impact factor: 7.396

2.  Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists.

Authors:  Doris M Benbrook; Scott A Kamelle; Suresh B Guruswamy; Stan A Lightfoot; Teresa L Rutledge; Natalie S Gould; Bethany N Hannafon; S Terence Dunn; K Darrell Berlin
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

3.  Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.

Authors:  Doris Mangiaracina Benbrook; Suresh Guruswamy; Yuhong Wang; Zhongjie Sun; Altaf Mohammed; Yuting Zhang; Qian Li; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2013-07-12

4.  Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria.

Authors:  Tongzu Liu; Bethany Hannafon; Lance Gill; William Kelly; Doris Benbrook
Journal:  Mol Cancer Ther       Date:  2007-06       Impact factor: 6.261

5.  Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.

Authors:  Tashanna Myers; Shylet Chengedza; Stan Lightfoot; Yanfang Pan; Daynelle Dedmond; Lauren Cole; Yuhong Tang; Doris M Benbrook
Journal:  Invest New Drugs       Date:  2008-09-18       Impact factor: 3.850

6.  Heteroarotinoids with anti-cancer activity against ovarian cancer cells.

Authors:  Thanh C Le; K Darrell Berlin; Stacy D Benson; Margaret A Eastman; Gianna Bell-Eunice; Anna C Nelson; Doris M Benbrook
Journal:  Open Med Chem J       Date:  2007-10-24

7.  Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug.

Authors:  Johnny Hyde; Doris M Benbrook
Journal:  Am J Pharmacol Toxicol       Date:  2006-01-01

Review 8.  Role of adaptor protein p66Shc in renal pathologies.

Authors:  Kevin D Wright; Alexander Staruschenko; Andrey Sorokin
Journal:  Am J Physiol Renal Physiol       Date:  2017-10-04

9.  Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.

Authors:  Katherine Marie Moxley; Shylet Chengedza; Doris Mangiaracina Benbrook
Journal:  Gynecol Oncol       Date:  2009-10-04       Impact factor: 5.482

10.  Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention.

Authors:  Doris M Benbrook; Stan Lightfoot; James Ranger-Moore; Tongzu Liu; Shylet Chengedza; William L Berry; Igor Dozmorov
Journal:  Gene Regul Syst Bio       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.